English
- 中文
- English
- 繁体
- 日本語
- 한국어
- Español
- ພາສາລາວ
- ภาษาไทย
- Pусский
- Français
- Italiano
- Deutsch
- Português
- Tiếng Việt
- Bahasa Melayu
- Filipino
- हिन्दी
- កម្ពុជា។
- Català
- Српски
- íslenskur
- বাংলা
- Українська
- עברית
- فارسی
- Slovenščina
- Slovenský jazyk
- Hrvatski
- Eesti keel
- latviski
- lietuvių kalba
- Magyar
- Română
- Български
- Nederlands
- Čeština
- Dansk
- Suomi
- Ελληνικά
- Bahasa Indonesia
- lëtzebuergesch
- Norsk
- Svenska
- Polski
Make Precision Medicine More Accessible
Light-initiated Chemiluminesence System
High sensitivity, no need for cold chain storage and transportation, whole blood testing, no additional consumables
Xenta Light-initiated Chemiluminesence System
X-Lab mini LOCl lmmunoanalyzer
Xenta Rapid Test Kits System
Rapid Test Kits
Xenta Fluorescent Lateral Flow Immunoassay
Fluorescent Immuno - analyzer X - FIA - 300
Xenta PCR System
Xenta M-chip PCR system
0
+SCI papers
0
+Domestic and international patents
0
+EU certification
0
itemsUS FDA certification
About Xenta Biomedical Science Co.Ltd/ABOUT US
Focus on the development of faster, better, and more accessible diagnostic products
Xenta Biomedical Science Co.Ltd. was established in December 2021. Its headquarters is located in Guangzhou Development Zone. It is a national high - tech enterprise focusing on the R & D, registration, and industrialization of in - vitro diagnostic reagents and equipment. Founded by a team of returnee doctors with many years of overseas scientific research and industrialization experience, it adheres to the product concept of "Faster, more accurate, and more accessible" and is committed to the development of innovative POCT technology platforms and global market layout.
R & D ability is the core driving force of Xenta Biomedical Science Co.Ltd. The company has R & D centers in Guangzhou, Xiamen, and overseas. Relying on its independently developed dry laser chemiluminescence POCT technology platform, it has successfully developed a number of product series with leading domestic and international levels. The team has presided over many national, provincial, and municipal scientific research projects, including the "13th Five - Year Plan" major project. It has published more than 20 SCI papers in total, applied for and obtained more than 70 domestic and international patents, and won honors such as the second prize of Hainan Provincial Science and Technology Progress Award. Currently, the company has obtained more than 60 EU CE certifications and 12 US FDA certifications. Its R & D pipeline covers major disease areas such as cardiovascular and cerebrovascular diseases, inflammation, tumors, hormones, and infectious diseases, demonstrating its full - chain R & D strength from technological originality, product transformation to global registration.
NewsInformation/NEWS
Business distribution/BUSINESS
Let precision medicine spread across the globe
Contact us/CONTACT
Phone: 400-133-5789
Email: market@xentabms.com
Address: Room 901, Building C5, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou City
Inquiry
If you have relevant cooperation intentions, welcome to leave us a message
表单1
Company*
Phone*
Email*
Theme*
Information*
©2025 Xenta Biomedical Science Co., Ltd. All rights reserved.